Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2022-02-14 Report Publication Anno…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Invitation to Q4 2021 result presentation
Report Publication Announcement Classification · 98% confidence The document is an invitation to a presentation for the company's Q4 and preliminary full-year 2021 results, scheduled for February 18, 2022. Crucially, it states: "PCI Biotech's Q4 and preliminary full-year 2021 interim report will be released on 18 February 2022 at 07.00 CET." This document is an announcement *about* the upcoming release of an interim report and the associated presentation, not the report itself. Since it announces the publication of a periodic financial report (Interim Report), the most fitting category is Report Publication Announcement (RPA). It is short and serves to inform the market about the release timing, aligning with the 'MENU VS MEAL' rule.
2022-02-14 English
PCI Biotech: Update on the RELEASE trial
Legal Proceedings Report Classification · 99% confidence The document is a press release dated January 24, 2022, announcing a strategic decision by PCI Biotech to stop the RELEASE clinical study due to new competitive data from an ASCO GI presentation. It discusses financial position, future development focus (fimaVacc, fimaNAc), and crucially, announces a webcast/conference call scheduled for January 25, 2022, including dial-in details and a Q&A session. This content perfectly matches the definition of a Call Transcript (CT) if it were the transcript itself, or an Earnings Release (ER) if it were the primary results announcement. However, since it is an announcement *about* a strategic decision and *announcing* a conference call to elaborate on it, it functions as a general corporate update that precedes the call. Given the options, it is a significant corporate announcement. It is not a 10-K, AR, or IR. It is not a formal DIV, DIRS, or SHA. The announcement of a conference call to discuss strategic changes and results often falls under Earnings Release (ER) if it relates to period results, or Regulatory Filings (RNS) if it's a general update. Since it discusses strategic shifts and cash position following clinical data, it is most closely aligned with an Earnings Release (ER) or a general Regulatory Filing (RNS). Because it is a specific, material announcement about clinical trial strategy and includes details for an upcoming call, it is best classified as an Earnings Release (ER) or a general Regulatory Filing (RNS). Given the context of clinical trial updates and financial positioning, ER is often used for such material updates, even if not strictly quarterly results. However, the presence of dial-in details for a conference call strongly suggests this is the precursor to a Call Transcript (CT) or an Earnings Release (ER). Since it is not the transcript itself, and it's a material update, ER is a strong candidate. If it were purely a miscellaneous regulatory notice, RNS would apply. I will classify it as an Earnings Release (ER) as it provides key operational and financial updates, even if not tied to a standard quarterly filing date, and announces a call to discuss them.
2022-01-24 English
PCI Biotech: Publication of preclinical tuberculosis results
Environmental & Social Information Classification · 99% confidence The document is a short announcement dated January 11, 2022, stating that results from preclinical studies on tuberculosis have been accepted for publication in a scientific journal ('Frontiers in Immunology'). It provides the title and a link to the abstract. Since the document is short (3332 characters) and its primary function is to announce the publication of external scientific findings rather than being the full report itself, it fits the description of a Report Publication Announcement (RPA). It is not a formal regulatory filing like 10-K, ER, or IR, nor is it a general regulatory announcement (RNS) as RPA is more specific for announcing the release/publication of reports/findings.
2022-01-11 English
PCI Biotech and MDimune announce research collaboration agreement
Regulatory Filings Classification · 95% confidence The document is a press release announcing a 'research collaboration agreement' between two biotech companies, PCI Biotech and MDimune. It details the nature of the agreement, includes quotes from CEOs, and provides background information on both companies. This type of announcement, which details a strategic partnership or business development that is not a standard financial filing (like 10-K, ER, or IR), typically falls under general corporate news or regulatory filings. Since it is not a specific financial report, management change, dividend notice, or capital event, and it is a formal announcement of a business development, the most appropriate general category is 'Regulatory Filings' (RNS) as a catch-all for significant corporate news that doesn't fit the highly specific financial codes. However, given the context of strategic business development, it is often classified as a general corporate announcement. Since there is no specific code for 'Partnership Announcement', RNS is the best fit among the provided options for a non-standard, material corporate update.
2022-01-05 English
PCI Biotech and MDimune announce research collaboration agreement
Regulatory Filings Classification · 100% confidence The document announces a 'research collaboration agreement' between two companies, PCI Biotech and MDimune. It is a short press release format, dated January 5, 2022. Crucially, the text ends with the statement: 'Please see the attachment for the full press release.' This indicates the provided text is an announcement about the existence of a more detailed document (the full press release), rather than the full report itself. Since this is a specific corporate announcement that doesn't fit the definitions for M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), and it is an announcement of information rather than the core financial report, it best fits the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory announcements not covered elsewhere. Given the context of a press release announcing a specific business event, RNS is the most appropriate classification.
2022-01-05 English
PCI Biotech to present at DNB Nordic Healthcare Conference 2021
Regulatory Filings Classification · 90% confidence The document announces that PCI Biotech has been invited to present at the DNB Nordic Healthcare Conference 2021 on December 16, 2021. It details the time, presenter (CEO), and the nature of the presentation (overview of proprietary platform technology). This is a communication about an upcoming investor/industry event, not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed investor presentation (IP) itself, although it relates to investor relations. Since it is an announcement regarding participation in an external event, and it doesn't fit the specific categories like DIV, DIRS, or MANG, it falls best under the general 'Regulatory Filings' (RNS) category as a general corporate announcement, or potentially related to investor relations activities. Given the options, RNS serves as the best general announcement category for non-standard corporate news that isn't a core financial report or management change.
2021-12-14 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.